In humans living with overweight/obesity, infusion of GIP at a dose of 4–6 pmol/kg/min for 4–5 h even abolished food intake inhibition of simultaneously infused GLP-1 [181], or revealed no effect relative to treatment with GLP-1 alone [960]. Here, GLP1R is linked to obesity disorder.